Literature DB >> 8501539

p53 immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix.

S Bosari1, M Roncalli, G Viale, P Bossi, G Coggi.   

Abstract

Immunoreactivity for the tumour suppressor gene product p53 is commonly found in many different human malignancies and few premalignant lesions. Data on cervical neoplasms, however, are still lacking. We retrospectively investigated p53 immunoreactivity in 92 lesions of the uterine cervix, including 44 cases of chronic cervicitis, 29 squamous intraepithelial lesions (SILs), and 19 invasive carcinomas. p53 immunoreactivity, confined to the basal cell layer, was detected in 74 per cent of cases showing chronic cervicitis and in all cases with low-grade SILs. Conversely, suprabasal and/or diffuse p53 immunoreactivity was exclusively demonstrated in 25 per cent of high-grade SILs and in 74 per cent of invasive carcinomas. The results of this investigation document a high prevalence of p53-immunoreactive malignant tumours of the uterine cervix. In high-grade SILs, p53-immunoreactive cells paralleled the height of involvement by dysplastic changes within the squamous epithelium. A prolonged half-life of the protein is the most likely explanation for the occurrence of p53 immunoreactivity in neoplastic cells. The unexpected finding of p53-immunoreactive cells in inflammatory lesions, though possibly related to an increased proliferation rate of the basal cell compartment, requires further study and underlines the need for a careful approach to p53 immunocytochemistry.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501539     DOI: 10.1002/path.1711690407

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  13 in total

1.  Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation.

Authors:  S V Litvinov; W van Driel; C M van Rhijn; H A Bakker; H van Krieken; G J Fleuren; S O Warnaar
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

2.  p53 expression in carcinoma of the cervix.

Authors:  C R Hunt; R J Hale; C H Buckley; J Hunt
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

3.  Interphase cytogenetic analysis of cervical intraepithelial neoplasia.

Authors:  J Bulten; P J Poddighe; J C Robben; J H Gemmink; P C de Wilde; A G Hanselaar
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

4.  Germline mutations of TP53 gene in breast cancer.

Authors:  Surekha Damineni; Vadlamudi Raghavendra Rao; Satish Kumar; Rajasekar Reddy Ravuri; Sailaja Kagitha; Nageswara Rao Dunna; Raghunadharao Digumarthi; Vishnupriya Satti
Journal:  Tumour Biol       Date:  2014-06-15

5.  p53 Overexpression in laryngeal squamous cell carcinoma and dysplasia.

Authors:  C Barbatis; L Loukas; M Grigoriou; I Nikolaou; A Tsikou-Papafragou; N Marsan; K C Gatter; L Kaklamanis
Journal:  Clin Mol Pathol       Date:  1995-08

6.  p53 immunohistochemical expression of Egyptian cervical carcinoma.

Authors:  H Abd El All; A Rye; P Duvillard
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

7.  p53 immunoreactivity in cervical intraepithelial neoplasia and non-neoplastic cervical squamous epithelium.

Authors:  M D Jeffers; J Richmond; M Farquharson; A M McNicol
Journal:  J Clin Pathol       Date:  1994-12       Impact factor: 3.411

8.  Immunohistochemical detection of p53 in cervical epithelial lesions with or without infection of human papillomavirus types 16 and 18.

Authors:  M Akasofu; Y Oda
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

9.  The Role of p53 Gene in Cervical Carcinogenesis.

Authors:  Sulekha Pandey; L K Pandey; A K Saxena; Nidhi Patel
Journal:  J Obstet Gynaecol India       Date:  2015-09-04

10.  p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma.

Authors:  S Bosari; G Viale; M Roncalli; D Graziani; G Borsani; A K Lee; G Coggi
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.